Replimune Group, Inc.

NasdaqGS:REPL Stock Report

Market Cap: US$1.0b

Replimune Group Valuation

Is REPL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of REPL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: REPL ($14.93) is trading below our estimate of fair value ($25.94)

Significantly Below Fair Value: REPL is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for REPL?

Key metric: As REPL is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for REPL. This is calculated by dividing REPL's market cap by their current book value.
What is REPL's PB Ratio?
PB Ratio2.7x
BookUS$381.46m
Market CapUS$1.02b

Price to Book Ratio vs Peers

How does REPL's PB Ratio compare to its peers?

The above table shows the PB ratio for REPL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.5x
AUTL Autolus Therapeutics
1.6x50.6%US$782.4m
AVXL Anavex Life Sciences
6x47.7%US$772.5m
RLAY Relay Therapeutics
0.9x-4.7%US$795.1m
PRTA Prothena
1.5x38.5%US$785.6m
REPL Replimune Group
2.7x21.0%US$1.0b

Price-To-Book vs Peers: REPL is expensive based on its Price-To-Book Ratio (2.7x) compared to the peer average (2.5x).


Price to Book Ratio vs Industry

How does REPL's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$554.58m
IMAB I-Mab
0.4x1.8%US$76.59m
ACET Adicet Bio
0.4x6.7%US$74.16m
MGX Metagenomi
0.3x-23.2%US$70.73m
REPL 2.7xIndustry Avg. 1.9xNo. of Companies81PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: REPL is expensive based on its Price-To-Book Ratio (2.7x) compared to the US Biotechs industry average (1.9x).


Price to Book Ratio vs Fair Ratio

What is REPL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REPL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate REPL's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst REPL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$14.93
US$16.50
+10.5%
7.4%US$18.00US$14.00n/a8
Nov ’25US$11.90
US$15.50
+30.3%
9.7%US$17.00US$13.00n/a8
Oct ’25US$11.90
US$15.67
+31.7%
9.5%US$17.00US$13.00n/a9
Sep ’25US$10.17
US$14.89
+46.4%
12.0%US$17.00US$12.00n/a9
Aug ’25US$10.22
US$14.33
+40.2%
16.8%US$17.00US$10.00n/a9
Jul ’25US$9.36
US$14.33
+53.1%
16.8%US$17.00US$10.00n/a9
Jun ’25US$5.27
US$13.56
+157.2%
18.1%US$19.00US$10.00n/a9
May ’25US$6.48
US$13.56
+109.2%
18.1%US$19.00US$10.00n/a9
Apr ’25US$7.73
US$13.56
+75.4%
18.1%US$19.00US$10.00n/a9
Mar ’25US$8.97
US$13.56
+51.1%
18.1%US$19.00US$10.00n/a9
Feb ’25US$7.86
US$13.00
+65.4%
19.5%US$19.00US$10.00n/a9
Jan ’25US$8.43
US$13.00
+54.2%
19.5%US$19.00US$10.00n/a9
Dec ’24US$11.71
US$48.44
+313.7%
22.3%US$70.00US$32.00n/a9
Nov ’24US$14.29
US$49.22
+244.5%
20.9%US$70.00US$33.00US$11.909
Oct ’24US$17.11
US$49.22
+187.7%
20.9%US$70.00US$33.00US$11.909
Sep ’24US$19.72
US$49.22
+149.6%
20.9%US$70.00US$33.00US$10.179
Aug ’24US$20.54
US$51.90
+152.7%
18.2%US$70.00US$33.00US$10.2210
Jul ’24US$23.22
US$51.90
+123.5%
18.2%US$70.00US$33.00US$9.3610
Jun ’24US$18.48
US$50.60
+173.8%
20.4%US$70.00US$33.00US$5.2710
May ’24US$17.50
US$50.70
+189.7%
20.1%US$70.00US$34.00US$6.4810
Apr ’24US$17.66
US$51.44
+191.3%
20.3%US$70.00US$34.00US$7.739
Mar ’24US$22.31
US$52.10
+133.5%
19.4%US$70.00US$34.00US$8.9710
Feb ’24US$28.59
US$51.50
+80.1%
20.9%US$70.00US$34.00US$7.8610
Jan ’24US$27.20
US$50.56
+85.9%
21.7%US$70.00US$34.00US$8.439
Dec ’23US$19.98
US$44.80
+124.2%
18.8%US$60.00US$30.00US$11.7110
Nov ’23US$19.06
US$45.90
+140.8%
21.1%US$60.00US$30.00US$14.2910

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies